Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (GB:0HA3)
LSE:0HA3
RESEARCH TOOLSreports
Holding GB:0HA3?
Track your performance easily
0HA3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.43 - $29.50
Previous Close$7.4
Volume1.17K
Average Volume (3M)2.53K
Market Cap
$158.29M
Enterprise Value$58.36M
Total Cash (Recent Filing)$173.83M
Total Debt (Recent Filing)$73.89M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Nov 07, 2024EPS Estimate
-$1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding20,800,903
10 Day Avg. Volume1,864
30 Day Avg. Volume2,533
Standard Deviation0.25
R-Squared0.00814
Alpha-0.00583
Financial Highlights & Ratios
Price to Book (P/B)0.93
Price to Sales (P/S)43.97
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.21
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$26.00Price Target Upside251.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Adverum Biotechnologies News
Bulls Say, Bears Say
Bulls Say
Clinical Trial MilestonesThe recent landmark 26-week interim analysis from the Phase 2 LUNA trial reflected the potential best-in-class profile for injection freedom with a favorable safety profile at 26 weeks.
Financial PerformanceReported OpEx was lower than expected, with the cash runway guidance maintained as late 2025.
Regulatory SupportIxo-vec received Regenerative Medicine Advanced Therapy (RMAT) designation from FDA, with RMAT designation providing opportunities for expedited product development, including potential priority review of any biologics license application.
Bears Say
Competition4D-150 is the most direct competitor to ADVM's ixo-vec, with a first Phase 3 study expected to begin in 1Q25.
Financial PositionThe company will need to fortify its current cash position in order to fully fund the Ph. III program.
Safety ConcernsSafety concerns around intraocular inflammation (IOI) appear to be a major gating factor for whether KOLs feel comfortable offering gene therapies to their patients.
---
0HA3 FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest share price was $6.43 and its highest was $29.50 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Currently, no data Available
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is Nov 07, 2024 which is in 27 days.
How were Adverum Biotechnologies’s earnings last quarter?
Adverum Biotechnologies released its earnings results on Aug 12, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.468 by $0.578.
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate is -$1.36.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 20,800,903 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Adverum Biotechnologies reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.468. Following the earnings report the stock price went up 3.108%.
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Among the largest hedge funds holding Adverum Biotechnologies’s share is Versant Venture Management, LLC. It holds Adverum Biotechnologies’s shares valued at 3M.
---
Adverum Biotechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (251.49% Upside)
$26.00 (251.49% Upside)
Blogger Sentiment
Bullish
GB:0HA3 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.54%
12-Months-Change
Fundamentals
Return on Equity
-66.76%
Trailing 12-Months
Asset Growth
5.13%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
---
0HA3 Stock 12 Month Forecast
Average Price Target
$26.00
▲(251.49% Upside)
Technical Analysis
Adverum Biotechnologies
―
Editas Medicine
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering 0HA3
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-27.08%
assigned a buy rating 21 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -27.08% per trade.
---